{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407396353
| IUPAC_name = 2-Methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one
| image = Ibudilast.svg
| width = 150

<!--Clinical data-->
| tradename = Ketas, Pinatos, Eyevinal
| Drugs.com = {{drugs.com|international|ibudilast}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Rx-only <small>([[Japan|JP]])</small>
| routes_of_administration = [[Oral administration|By mouth]] ([[Capsule (pharmacy)|capsules]]),<br /> [[Topical medication|topical]] ([[Eye drop|ophthalmic solution]])

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7399
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50847-11-5
| ATC_prefix = R03
| ATC_suffix = DC04
| PubChem = 3671
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB05266
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 3543
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = M0TTH61XC5
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01385
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 19449

<!--Chemical data-->
| C=14 | H=18 | N=2 | O=1 
| molecular_weight = 230.31 g/mol
| SMILES = CC(C)C(=O)c1c(nn2ccccc12)C(C)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ZJVFLBOZORBYFE-UHFFFAOYSA-N
}}

'''Ibudilast''' (development codes: '''AV-411''' or '''MN-166''') is an [[anti-inflammatory]] drug used mainly in Japan, which acts as a [[phosphodiesterase inhibitor]], inhibiting the [[Phosphodiesterase 4|PDE4]] subtype to the greatest extent,<ref>{{cite journal | last1 = Huang | first1 = Z | last2 = Liu | first2 = S | last3 = Zhang | first3 = L | last4 = Salem | first4 = M | last5 = Greig | first5 = GM | last6 = Chan | first6 = CC | last7 = Natsumeda | first7 = Y | last8 = Noguchi | first8 = K | date = May 2006 | title = Preferential inhibition of human phosphodiesterase 4 by ibudilast | url = | journal = Life Sciences | volume = 78 | issue = 23| pages = 2663–8 | doi=10.1016/j.lfs.2005.10.026}}</ref> but also showing significant inhibition of other PDE subtypes.<ref>{{cite journal | last1 = Suzumura | first1 = A | last2 = Ito | first2 = A | last3 = Yoshikawa | first3 = M | last4 = Sawada | first4 = M | date = Aug 1999 | title = Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS | url = | journal = Brain Research | volume = 837 | issue = 1–2| pages = 203–12 | doi=10.1016/s0006-8993(99)01666-2}}</ref><ref>Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. ''European Journal of Pharmacology''. 2006 May 24;538(1-3):39-42.</ref>

Ibudilast has [[bronchodilator]], [[vasodilator]]<ref>{{cite journal | last1 = Kishi | first1 = Y | last2 = Ohta | first2 = S | last3 = Kasuya | first3 = N | last4 = Sakita | first4 = S | last5 = Ashikaga | first5 = T | last6 = Isobe | first6 = M | date = Fall 2001 | title = Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall | url = | journal = Cardiovascular Drug Reviews | volume = 19 | issue = 3| pages = 215–25 }}</ref> and [[Neuroprotection|neuroprotective]] effects,<ref>Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Jacob Linder, Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. ''Neuropharmacology''. 2004 Mar;46(3):404-11.</ref><ref>{{cite journal | last1 = Yoshioka | first1 = M | last2 = Suda | first2 = N | last3 = Mori | first3 = K | last4 = Ueno | first4 = K | last5 = Itoh | first5 = Y | last6 = Togashi | first6 = H | last7 = Matsumoto | first7 = M | date = Apr 2002 | title = Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia | url = | journal = Pharmacological Research | volume = 45 | issue = 4| pages = 305–11 | doi=10.1006/phrs.2002.0949}}</ref> and is mainly used in the treatment of [[asthma]] and [[stroke]].<ref>{{cite journal | last1 = Wakita | first1 = H | last2 = Tomimoto | first2 = H | last3 = Akiguchi | first3 = I | last4 = Lin | first4 = JX | last5 = Ihara | first5 = M | last6 = Ohtani | first6 = R | last7 = Shibata | first7 = M | date = Nov 2003 | title = Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat | url = | journal = Brain Research | volume = 992 | issue = 1| pages = 53–9 | doi=10.1016/j.brainres.2003.08.028}}</ref> It inhibits [[platelet]] aggregation,<ref>{{cite journal | last1 = Rile | first1 = G | last2 = Yatomi | first2 = Y | last3 = Qi | first3 = R | last4 = Satoh | first4 = K | last5 = Ozaki | first5 = Y | date = May 2001 | title = Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells | url = | journal = [[Thrombosis Research]] | volume = 102 | issue = 3| pages = 239–46 | doi=10.1016/s0049-3848(01)00258-4}}</ref> and may also be useful in the treatment of [[multiple sclerosis]].<ref>{{cite journal | last1 = Feng | first1 = J | last2 = Misu | first2 = T | last3 = Fujihara | first3 = K | last4 = Sakoda | first4 = S | last5 = Nakatsuji | first5 = Y | last6 = Fukaura | first6 = H | last7 = Kikuchi | first7 = S | last8 = Tashiro | first8 = K | last9 = Suzumura | first9 = A | last10 = Ishii | first10 = N | last11 = Sugamura | first11 = K | last12 = Nakashima | first12 = I | last13 = Itoyama | first13 = Y | date = Oct 2004 | title = Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis | url = | journal = Multiple Sclerosis | volume = 10 | issue = 5| pages = 494–8 | doi=10.1191/1352458504ms1070oa}}</ref>

Ibudilast crosses the [[blood–brain barrier]] and suppresses [[glial cell]] activation. This activity has been shown to make ibudilast useful in the treatment of [[neuropathic pain]] and it not only enhances [[Analgesic|analgesia]] produced by [[opioid]] drugs, but also reduces the development of [[Drug tolerance|tolerance]].<ref>{{cite journal | last1 = Ledeboer | first1 = A | last2 = Hutchinson | first2 = MR | last3 = Watkins | first3 = LR | last4 = Johnson | first4 = KW | date = Jul 2007 | title = Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes | url = | journal = Expert Opinion on Investigational Drugs | volume = 16 | issue = 7| pages = 935–50 | doi=10.1517/13543784.16.7.935}}</ref>

It may have some use reducing methamphetamine<ref>http://www.huffingtonpost.com/2013/04/03/meth-addiction-cure-ucla-ibudilast_n_2863126.html</ref> and alcohol<ref>{{cite journal|doi=10.1111/adb.12106 | volume=20 | title=Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence | journal=Addiction Biology | pages=38–42 | last1 = Bell | first1 = Richard L.}}</ref> addiction.

Ibudilast is listed as being an [[Receptor antagonist|antagonist]] at the [[toll-like receptor]] 4 ([[TLR4]]).<ref>{{Cite journal|last=Jia|first=Ze-jun|last2=Wu|first2=Fei-xiang|last3=Huang|first3=Qing-hai|last4=Liu|first4=Jian-min|date=2012-04-01|title=[Toll-like receptor 4: the potential therapeutic target for neuropathic pain]|journal=Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae|volume=34|issue=2|pages=168–173|doi=10.3881/j.issn.1000-503X.2012.02.013|issn=1000-503X|pmid=22776604}}</ref> This likely play an immense part in its effect, specifically its synergy with opioid drugs, its [[anti-inflammatory]] effect, and its own [[Analgesic|painkilling]] effect.<ref>{{Cite journal|last=Hutchinson|first=Mark R.|last2=Zhang|first2=Yingning|last3=Shridhar|first3=Mitesh|last4=Evans|first4=John H.|last5=Buchanan|first5=Madison M.|last6=Zhao|first6=Tina X.|last7=Slivka|first7=Peter F.|last8=Coats|first8=Benjamen D.|last9=Rezvani|first9=Niloofar|date=2010-01-01|title=Evidence that opioids may have toll like receptor 4 and MD-2 effects|journal=Brain, behavior, and immunity|volume=24|issue=1|pages=83–95|doi=10.1016/j.bbi.2009.08.004|issn=0889-1591|pmc=2788078|pmid=19679181}}</ref> It is unknown if the PDE4-inhibiting properties [[Drug synergy|potentiate]] the effects of TLR4 inactivation and/or vice versa, despite that some of their effects are shared, such as [[inflammation]] reducing properties.<ref>{{Cite journal|last=Jin|first=S.-L. Catherine|last2=Ding|first2=Shiau-Li|last3=Lin|first3=Shih-Chang|date=2012-06-01|title=Phosphodiesterase 4 and its inhibitors in inflammatory diseases|journal=Chang Gung Medical Journal|volume=35|issue=3|pages=197–210|issn=2309-835X|pmid=22735051|doi=10.4103/2319-4170.106152}}</ref>

TLR4 antagonists theoretically reverse the increase in pain and inflammation caused by most TLR4 [[agonist]]s, which include many [[opiate]] and [[opioid]] drugs.<ref>{{Cite journal|last=Komatsu|first=Takaaki|last2=Sakurada|first2=Shinobu|last3=Katsuyama|first3=Sou|last4=Sanai|first4=Kengo|last5=Sakurada|first5=Tsukasa|date=2009-01-01|title=Mechanism of allodynia evoked by intrathecal morphine-3-glucuronide in mice|journal=International Review of Neurobiology|volume=85|pages=207–219|doi=10.1016/S0074-7742(09)85016-2|issn=0074-7742|pmid=19607972}}</ref>

==Medical uses==
In [[Japan]], ibudilast oral capsules are approved for the treatment of [[asthma]], and for improvement of [[dizziness]] secondary to chronic cerebral circulation impairment associated with sequelae of [[cerebral infarction]].<ref name="Ketas PI">{{cite web|title=Ketas (ibudilast) Capsules 10 mg. Prescribing Information|url=http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/KETAS_Capsules.pdf|publisher=Kyorin Pharmaceutical Co., Ltd.|accessdate=3 October 2016}}</ref> Ibudilast ophthalmic solution is indicated for the treatment of [[allergic conjunctivitis]] and [[Allergic rhinitis|hay fever]].<ref>{{cite web|title=Ketas (ibudilast) Eye Drops 0.01% Kisuri-no-Shiori (Drug Information Sheet)|url=http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1744|publisher=Senju Pharmaceutical Co., Ltd.|accessdate=3 October 2016}}</ref>

==References==
{{reflist|2}}

{{Drugs for obstructive airway diseases}}
{{Phosphodiesterase inhibitors}}

[[Category:Pyrazolopyridines]]
[[Category:PDE4 inhibitors]]